127 related articles for article (PubMed ID: 32968225)
1. The failure to fail smartly.
Galson S; Austin CP; Khandekar E; Hudson LD; DiMasi JA; Califf R; Wagner JA
Nat Rev Drug Discov; 2021 Apr; 20(4):259-260. PubMed ID: 32968225
[No Abstract] [Full Text] [Related]
2. What are the economic barriers of antibiotic R&D and how can we overcome them?
Renwick M; Mossialos E
Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
[No Abstract] [Full Text] [Related]
3. The pharmaceutical industry needs more clinical pharmacologists.
Peck R
Br J Clin Pharmacol; 2017 Nov; 83(11):2343-2346. PubMed ID: 28688130
[No Abstract] [Full Text] [Related]
4. PhRMA: Placing Prescription Drugs into Context.
Lindsley CW
ACS Chem Neurosci; 2016 Oct; 7(10):1312. PubMed ID: 27756135
[No Abstract] [Full Text] [Related]
5. R&D efficiency of leading pharmaceutical companies - A 20-year analysis.
Schuhmacher A; Wilisch L; Kuss M; Kandelbauer A; Hinder M; Gassmann O
Drug Discov Today; 2021 Aug; 26(8):1784-1789. PubMed ID: 34022459
[TBL] [Abstract][Full Text] [Related]
6. The Economic Conundrum for Antibacterial Drugs.
Shlaes DM
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658969
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on the Role of Mathematics in Drug Discovery and Development.
Allen R; Moore H
Bull Math Biol; 2019 Sep; 81(9):3425-3435. PubMed ID: 30693431
[TBL] [Abstract][Full Text] [Related]
8. Recommendations toward a human pathway-based approach to disease research.
Marshall LJ; Austin CP; Casey W; Fitzpatrick SC; Willett C
Drug Discov Today; 2018 Nov; 23(11):1824-1832. PubMed ID: 29870792
[TBL] [Abstract][Full Text] [Related]
9. Strategic balance of drug lifecycle management options differs between domestic and foreign companies in Japan.
Yamanaka T; Kano S
Expert Opin Ther Pat; 2016; 26(4):497-503. PubMed ID: 26881292
[TBL] [Abstract][Full Text] [Related]
10. Integrating dose estimation into a decision-making framework for model-based drug development.
Dunyak J; Mitchell P; Hamrén B; Helmlinger G; Matcham J; Stanski D; Al-Huniti N
Pharm Stat; 2018 Mar; 17(2):155-168. PubMed ID: 29322659
[TBL] [Abstract][Full Text] [Related]
11. Samantha Du.
Nat Rev Drug Discov; 2018 Nov; 17(12):856-857. PubMed ID: 30482961
[No Abstract] [Full Text] [Related]
12. Drug development: Time for teamwork.
May M
Nature; 2014 May; 509(7498):S4-5. PubMed ID: 24784427
[No Abstract] [Full Text] [Related]
13. The inherent risks associated with newly traded biopharmaceutical firms.
Williams DR; Spaulding TJ
Drug Discov Today; 2018 Sep; 23(9):1680-1688. PubMed ID: 29936246
[TBL] [Abstract][Full Text] [Related]
14. Review of companies and drug classes in the 2007-2011 antihypertensive patent literature.
Carpino PA; Flynn D
Pharm Pat Anal; 2012 Mar; 1(1):45-64. PubMed ID: 24236713
[TBL] [Abstract][Full Text] [Related]
15. Costly Genes.
Karayiorgou M
PLoS Genet; 2020 Aug; 16(8):e1008889. PubMed ID: 32817613
[No Abstract] [Full Text] [Related]
16. Windows of opportunities and technological innovation in the Brazilian pharmaceutical industry.
Tigre PB; Nascimento CV; Costa LS
Cad Saude Publica; 2016 Nov; 32Suppl 2(Suppl 2):e00103315. PubMed ID: 27828675
[TBL] [Abstract][Full Text] [Related]
17. Torching the Haystack: modelling fast-fail strategies in drug development.
Lendrem DW; Lendrem BC
Drug Discov Today; 2013 Apr; 18(7-8):331-6. PubMed ID: 23246516
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic development - economic, regulatory and societal challenges.
Årdal C; Balasegaram M; Laxminarayan R; McAdams D; Outterson K; Rex JH; Sumpradit N
Nat Rev Microbiol; 2020 May; 18(5):267-274. PubMed ID: 31745330
[No Abstract] [Full Text] [Related]
19. Bullying biosimilars: cheaper drugs stymied in USA.
The Lancet Gastroenterology Hepatology
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669
[No Abstract] [Full Text] [Related]
20. Is drug discovery dead?
Baldwin JJ
Future Med Chem; 2011 Nov; 3(15):1873-6. PubMed ID: 22023031
[No Abstract] [Full Text] [Related]
[Next] [New Search]
